Dihexa for Stroke Recovery & Post-Stroke Cognitive Impairment (PSCI): The 2026 UK Review

One stroke every five minutes. Around 100,000 strokes occur in the UK every year, and roughly 1.3 million people are living as stroke survivors — more than half of them with a stroke-related disability that the Stroke Association classes as life-altering. The acute pathway has transformed in the last decade — mechanical thrombectomy is steadily expanding under the NHS Long Term Plan, tenecteplase is moving towards parity with alteplase, and the 2025 European Stroke Organisation aphasia guideline has finally set a 20-hour minimum therapy dose. But the longer-term picture is harder. Around 60% of stroke survivors develop post-stroke cognitive impairment (PSCI) within twelve months, ranging from subtle executive slowing to fully vascular dementia. There is no NHS-licensed cognitive treatment specifically for PSCI or vascular dementia. Inside that gap, search interest in peptides for stroke recovery and Dihexa for post-stroke neuroplasticity has climbed sharply through 2025-2026. This is the rigorous 2026 UK review: does Dihexa actually engage stroke-recovery biology, what do the HGF/c-Met and BDNF stroke literatures really show, and where does an unlicensed peptide responsibly fit (or not fit) alongside NHS thrombectomy, secondary prevention and structured neurorehabilitation?

Stroke in the UK in 2026: 100,000 Events a Year, 1.3 Million Survivors, a Pathway Still Maturing

The headline numbers matter, and they have not really shifted in five years. The Stroke Association estimates around 100,000 strokes occur in the UK every year — roughly one every five minutes — with 1.3 million people now living as stroke survivors. Stroke is the UK's fourth-biggest killer after cancer, heart disease and dementia, and the single largest cause of adult acquired disability. More than half of stroke survivors live with a stroke-related disability that limits independence, and a substantial proportion never return to paid work. The House of Commons Library World Stroke Day briefing documents the wider public-health picture.

What has moved in 2025-2026 is the acute pathway. Mechanical thrombectomy is being expanded under the NHS Long Term Plan, with the goal of treating all eligible patients with large-vessel occlusion ischaemic stroke. Late-window and large-core trials have widened eligibility — approximately 15% of admitted UK stroke patients now meet thrombectomy criteria according to McMeekin and colleagues (2024) in the European Stroke Journal — though only around 25% of eligible patients currently receive the procedure because of workforce, capacity and geographic constraints. The Stroke Association's thrombectomy briefing shows that the procedure can increase functional independence at 90 days by 19-35 percentage points in eligible patients — one of the largest effect sizes in modern medicine.

The audit infrastructure is, by international standards, exceptionally strong. The Sentinel Stroke National Audit Programme (SSNAP) captures over 95% of UK hospital stroke admissions (~80,000 per year) with patient-level data from admission through to six-month follow-up. The 2025-2026 SSNAP cohort continues to demonstrate substantial regional variation in door-to-needle and door-to-puncture times, access to seven-day hyperacute stroke unit care, and access to early supported discharge and community rehabilitation.

The rehabilitation guidance is also clear, even if delivery is patchy. NICE NG236 (Stroke rehabilitation in adults), published in October 2023 and still the active guideline in 2026, recommends needs-based multidisciplinary rehabilitation of at least 3 hours per day on at least 5 days of the week, covering physiotherapy, occupational therapy, speech and language therapy, neuropsychology and clinical nursing input as required. The integrated community stroke service (ICSS) model coordinates transfer from hospital and provides home-based rehabilitation seven days per week in well-resourced areas.

What is far less well served is the cognitive trajectory after the acute event. PSCI, vascular cognitive impairment and post-stroke dementia have no NHS-licensed cognitive pharmacological treatment specifically indicated — cholinesterase inhibitors and memantine have modest effect sizes and are not licensed for pure vascular cognitive impairment. Community neuropsychology access varies sharply by region. The combination — 1.3 million survivors, 60% PSCI prevalence, no licensed cognitive drug, variable community rehab access — is exactly the environment in which interest in unlicensed neuroplasticity-targeted compounds flourishes.

The Biology of Post-Stroke Cognitive Impairment

Before asking whether Dihexa could plausibly help, it is worth being precise about what stroke-related cognitive impairment actually is. Stroke is structurally heterogeneous and the cognitive consequences differ substantially by lesion size, territory and pathology, but several biological features recur and are directly relevant to the synaptogenic-peptide question.

The Ischaemic Cascade and the Penumbra

Within minutes of arterial occlusion, neurons in the territory served by the blocked vessel lose ATP, fail to maintain ion gradients, depolarise, and trigger excitotoxic glutamate release. The core of the infarct is unrecoverable; the surrounding penumbra is hypoperfused but potentially salvageable if reperfusion occurs within a therapeutic window. This is the rationale for thrombolysis with alteplase or tenecteplase and for mechanical thrombectomy. Beyond reperfusion, the penumbra undergoes a prolonged period of vulnerability: microglial activation, secondary neuroinflammation, oxidative stress, glial scarring at the infarct edge and, over weeks to months, axonal sprouting and synaptic reorganisation that underwrite functional recovery.

The HGF/c-Met system is one of the most consistently identified endogenous repair signals across this timeline. The 2021 Frontiers review of HGF/MET in brain development and neurological disorders sets out the post-stroke biology in detail: HGF mRNA and protein rise in peri-infarct cortex within hours, c-Met is upregulated on surviving neurons and on endothelial cells, and the pathway mediates anti-apoptotic PI3K/AKT survival signalling, vascular repair and angiogenesis, and structural plasticity.

Haemorrhagic Stroke: A Different Biology

Roughly 15% of strokes in the UK are haemorrhagic — intracerebral haemorrhage from spontaneous vessel rupture (usually hypertensive small-vessel disease or amyloid angiopathy) or subarachnoid haemorrhage from a ruptured aneurysm. The mechanism of injury differs from ischaemic stroke: direct mechanical disruption, mass effect, secondary perihaematomal oedema, iron-toxicity-mediated injury from haem breakdown, and (in subarachnoid haemorrhage) delayed cerebral ischaemia from vasospasm. The recovery biology, however, converges on the same general principles — surviving neurons reorganise, axons sprout into denervated territory, and synaptic plasticity drives functional recovery. The HGF/c-Met and BDNF axes both contribute. No Dihexa data exist in haemorrhagic stroke specifically.

Small-Vessel Disease and Silent Strokes

A substantial component of vascular cognitive impairment derives not from a single dramatic stroke but from cumulative cerebral small-vessel disease — white-matter hyperintensities, lacunar infarcts, cerebral microbleeds and enlarged perivascular spaces visible on MRI. Many older adults carry MRI evidence of silent strokes they never noticed clinically. Pendlebury and Rothwell's update on dementia after TIA and stroke documents that small-vessel disease burden is a primary driver of cognitive decline trajectory across the older population, and the boundary with Alzheimer's pathology is increasingly seen as a mixed-pathology continuum rather than two distinct diseases.

For a synaptogenic peptide, this matters because cumulative small-vessel disease is biology where the synaptic-loss-as-cognitive-substrate framing — the same logic explored in the MCI and brain aging review — applies directly. The mechanistic case for an HGF/c-Met modulator in vascular cognitive impairment is, on paper, at least as strong as in MCI of mixed pathology. Whether that mechanistic case translates to clinical benefit in human PSCI is, again, untested.

The Cognitive Phenotype of PSCI

PSCI is not a single syndrome. Typical features include: slowed processing speed (the single most consistent finding), attention and executive dysfunction (planning, set-shifting, working memory), memory deficits (encoding and retrieval), and — depending on stroke territory — language deficits (aphasia, dominant-hemisphere strokes), visuospatial deficits (right-hemisphere or parietal strokes), and behavioural change. Approximately 60% of stroke patients show measurable cognitive impairment in the first year; about a third progress to severe enough cognitive deficits to meet vascular dementia criteria, and PSCI is associated with higher mortality and a 1.5-2x increased risk of recurrent stroke.

The cognitive trajectory is influenced by pre-stroke cognitive reserve, infarct volume and location, post-stroke depression (a major confound — see below), small-vessel disease burden, age, education, vascular-risk-factor control and access to structured rehabilitation. None of these are modifiable by a peptide; most are modifiable by NHS-licensed care.

The HGF/c-Met System in Stroke Recovery: What the Evidence Actually Shows

The strongest single biological argument for an HGF/c-Met-targeted peptide in stroke recovery rests on a substantial body of preclinical and translational work going back two decades. This is, in our editorial judgement, the strongest mechanistic case Dihexa has for any non-degenerative indication — though, as always, no human Dihexa data in stroke exist.

HGF Protein and Gene Transfer in Rodent Stroke Models

Endogenous HGF rises in peri-infarct cortex within hours of ischaemic stroke and remains elevated for weeks. Exogenous HGF given intravenously, intracerebroventricularly or via gene transfer reduces infarct volume in rodent middle cerebral artery occlusion (MCAO) models. The protective effect is multifactorial: anti-apoptotic PI3K/AKT signalling rescues neurons in the penumbra, endothelial c-Met activation promotes vascular repair and angiogenesis, and structural plasticity is supported by axonal sprouting from spared neurons into denervated territory. The Frontiers 2021 review of HGF/MET sets out the stroke-specific evidence with citations to the original primary literature.

A second strand of evidence comes from cell therapy. Brain repair mechanisms after cell therapy for stroke (Brain, 2024) documented that grafted stem cells improve outcomes partly through paracrine secretion of trophic factors including HGF, BDNF, GDNF and VEGF, suggesting the HGF/c-Met axis is a final-common-pathway target whether the upstream source is endogenous, gene-transferred, cell-secreted or pharmacologically potentiated.

Dihexa-Specific Stroke Preclinical Evidence

Dihexa-specific stroke data remain thin. The Wright and Harding 2015 Neuroscience review framed the AngIV-derived peptides for Alzheimer's and Parkinson's first; stroke and TBI were the next-most-cited indications, particularly because the underlying mechanism (HGF/c-Met activation, synaptogenesis, anti-apoptotic signalling) maps onto the post-stroke repair requirement directly. The closest in vivo Dihexa report relevant to vascular injury comes from Benoist and colleagues, who showed that the procognitive and synaptogenic effects of AngIV-derived peptides require HGF/c-Met activation — a finding that establishes the mechanism but does not directly demonstrate stroke benefit.

The closest TBI translational data are covered in detail on the TBI and concussion review and include the 2025 bioRxiv preprint in which an HGF/MET positive modulator dose-dependently rescued working memory deficits following repetitive mild TBI in rats. The mechanistic overlap between TBI and ischaemic stroke at the cellular level (neuronal injury, secondary neuroinflammation, axonal disconnection, synaptic loss, structural plasticity-driven recovery) is substantial — but transferring the TBI signal to human ischaemic stroke remains an inference rather than a finding.

Angiogenesis and Vascular Repair

One feature of HGF/c-Met biology that is particularly relevant in stroke is the pathway's role in vascular repair. c-Met is highly expressed on cerebral endothelial cells; HGF promotes endothelial survival, proliferation and angiogenesis in peri-infarct tissue. Post-stroke angiogenesis is a substrate for functional recovery: new microvasculature supports the metabolic demands of structural plasticity and axonal sprouting. This is one biological axis where HGF/c-Met activation arguably has a more direct mechanistic match in stroke than in neurodegeneration, where the deficit is primarily neuronal rather than vascular.

Microglial Activation and Neuroinflammation

Post-stroke inflammation has a dual character. Early microglial activation contributes to secondary injury at the infarct edge; later, microglial phagocytosis clears debris and supports tissue remodelling. HGF/c-Met activation has been shown to shift microglial polarisation towards a more reparative phenotype in several CNS contexts — the same logic explored in the Long COVID brain fog review. The relevance to stroke is direct: ongoing neuroinflammation contributes to delayed PSCI trajectory in many patients, and a peptide that modulates the inflammation-repair balance could in principle support cognitive recovery. This is, again, mechanism without human Dihexa data.

BDNF, Neuroplasticity and Why Rehabilitation is the Foundation

If the HGF/c-Met case rests on endogenous post-stroke repair signalling, the BDNF case rests on the substrate that underwrites every form of rehabilitation. Anyone considering a peptide that potentiates the BDNF/HGF axis should understand the existing evidence base for the rehabilitation interventions that already drive these signals.

BDNF in Stroke Recovery

Brain-derived neurotrophic factor (BDNF) is the dominant neuroplasticity-supporting neurotrophin in the adult human brain. BDNF supports neuronal survival, dendritic and axonal arborisation, synaptic plasticity, long-term potentiation and the structural remodelling that underwrites learning and memory. In stroke specifically, intravenous BDNF enhances post-stroke sensorimotor recovery and stimulates neurogenesis in the dentate gyrus in rodent ischaemia models. Higher endogenous serum BDNF after stroke has been associated, in some prospective cohorts, with better functional recovery — though this signal is heterogeneous across studies.

The functional relationship between BDNF and rehabilitation is bidirectional and increasingly well characterised. Aerobic exercise increases circulating BDNF: a 2023 Stroke meta-analysis documented statistically significant increases in serum BDNF after single sessions of exercise and after high-intensity aerobic exercise programmes in stroke survivors. A 2026 systematic review and meta-analysis found that cognitive-motor interventions significantly increase serum BDNF in stroke and older populations, supporting their role in driving rehabilitation-induced plasticity.

For the Dihexa question, this matters in two ways. First, the BDNF pathway is the rehabilitation substrate — meaning the highest-evidence post-stroke interventions all work, at least in part, through this axis. Second, the claim that Dihexa is many orders of magnitude more potent than BDNF is examined in detail elsewhere on the site; what matters here is that the mechanistic target is real and is the same target rehabilitation already engages.

Experience-Dependent Plasticity is Not Optional

The single most important principle of post-stroke neuroplasticity is that it is experience-dependent. Reorganisation of perilesional and contralateral cortex requires task-specific, intensive, repetitive practice — the rehabilitation principles of saliency, intensity, repetition, specificity and timing. There is no pharmacological shortcut around this. Even if a peptide successfully increased the substrate (BDNF, HGF/c-Met, dendritic spine density), without the experience-dependent practice that drives circuit-specific remodelling, the substrate remains potential rather than functional.

The practical implication is that anyone considering Dihexa for stroke recovery who is not already maximising structured rehabilitation — physiotherapy, occupational therapy, speech and language therapy, cognitive rehabilitation, exercise — has the order of operations backwards. The peptide is, at best, an adjunct to the work; it is not a substitute for the work.

Non-Invasive Brain Stimulation and Digital Rehabilitation

The 2025-2026 stroke recovery landscape includes increasingly promising data on non-invasive brain stimulation (transcranial direct current stimulation [tDCS], transcranial magnetic stimulation [TMS]), computer-based cognitive training, virtual reality-based rehabilitation, and machine-learning-supported personalisation. A 2026 network meta-analysis found that for patients with prominent cognitive deficits, combined computer-based cognitive training plus tDCS may be the optimal non-pharmacological option. These approaches share a substrate with BDNF/HGF-driven plasticity and are increasingly available in NHS and academic centres, including via the Manchester aphasia stimulation programme.

Post-Stroke Aphasia: The 2025 ESO Guideline and the Neuroplasticity Case

Around 30% of stroke survivors experience some form of aphasia — loss or impairment of language production, comprehension, repetition or naming. Aphasia is the single stroke deficit where the experience-dependent neuroplasticity story is clearest, and it is therefore the deficit where the mechanistic case for any plasticity-supporting peptide is most attractive.

The 2025 ESO Aphasia Guideline

The 2025 European Stroke Organisation (ESO) guideline on aphasia rehabilitation, led by Marian Brady and colleagues, is the most authoritative recent guidance. Its core recommendations are: speech and language therapy is effective for improving aphasia, language, communication and quality of life; total therapy dose should be at least 20 hours; therapy intensity and frequency should be higher rather than lower; individualised, group-based and digital delivery models are all supported. The guideline explicitly grounds these recommendations in the principles of experience-dependent neuroplasticity.

The UK delivery picture is heterogeneous. Acute hospital speech and language therapy is well established, but community SLT access for chronic aphasia (beyond the first three months) is variable. The Big CACTUS NIHR-funded trial demonstrated that computerised speech and language therapy added to usual care can deliver clinically meaningful improvements in word-finding for long-term post-stroke aphasia, supporting digital intensification of community therapy. Subsequent UK research has continued to explore intensification of dose and digital-delivery models.

Aphasia Recovery as Experience-Dependent Plasticity

Aphasia recovery proceeds through neuroplastic reorganisation: residual perilesional left-hemisphere language cortex takes on additional load, contralateral right-hemisphere homologues are recruited to varying degrees, and new functional networks form. Non-invasive brain stimulation studies have repeatedly shown that this reorganisation can be guided and accelerated. BDNF expression and HGF/c-Met signalling are central to the underlying cellular biology.

The mechanistic case for a synaptogenic peptide as an adjunct to intensive SLT is, on paper, attractive. The strongest mechanistic argument on this entire page might be: a peptide that potentiates HGF/c-Met and BDNF-driven plasticity, combined with the 20-hour minimum dose of structured SLT recommended by the 2025 ESO guideline, could in principle amplify the plasticity-driven language reorganisation that drives aphasia recovery. The reality is that no controlled human trial has tested this. The order of operations remains: maximise the SLT first; the peptide is, at most, an adjunct hypothesis without trial support.

Pharmacological Approaches to Aphasia

The pharmacological literature on aphasia is sparse and underwhelming. A 2022 review of pharmacological approaches documented modest signals for donepezil, memantine, piracetam and bromocriptine in selected aphasia phenotypes, but no agent has the trial base to justify routine clinical use. Dihexa has no published aphasia data at all. For someone with chronic aphasia in 2026, the realistic path remains: SLT to the 20-hour minimum, digital intensification, group communication therapy, and consideration of non-invasive brain stimulation in research-active centres.

Dihexa vs Standard Stroke Care in 2026

The honest comparison most readers want is between Dihexa and the interventions an NHS stroke pathway actually uses. As with Parkinson's disease, the comparison is mechanism-level misleading — these interventions operate on completely different parts of the disease — but worth working through.

Hyperacute Treatment: Reperfusion

Within the first hours of an ischaemic stroke, the only interventions that change outcomes meaningfully are reperfusion strategies: intravenous thrombolysis with alteplase or tenecteplase, and mechanical thrombectomy for large-vessel occlusion. Mechanical thrombectomy increases 90-day functional independence by 19-35 percentage points in eligible patients — an effect size unmatched by any pharmacological intervention. Dihexa has no role and could not realistically be administered in time even if it had one; the window for reperfusion is hours, the window for the peri-infarct repair signalling that an HGF/c-Met agent might engage is weeks to months.

Secondary Prevention

After the acute event, secondary prevention is the highest-yield intervention. The components are well-established: antiplatelets (clopidogrel for non-cardioembolic stroke, aspirin alone or in combination acutely), anticoagulation with a DOAC (apixaban, rivaroxaban, dabigatran, edoxaban) for atrial fibrillation, high-intensity statins for atherosclerotic stroke, blood pressure control (typically to target <130/80 in most patients), HbA1c optimisation, smoking cessation, alcohol within UK guidelines, structured exercise and weight management. The cumulative effect on recurrent stroke risk is large — the absolute risk reduction across the package is typically 60-80% relative to no treatment.

Dihexa interactions with any of these drugs are uncharacterised. The antiplatelet/anticoagulant combination is particularly important: an unstudied peptide added on top of clopidogrel, apixaban or warfarin without prescriber oversight is an unnecessary risk in a population whose haemorrhagic-conversion vulnerability is already elevated.

Multidisciplinary Rehabilitation

The NICE NG236 recommendation of at least 3 hours per day, 5 days per week of needs-based multidisciplinary rehabilitation remains the cornerstone of functional recovery. Physiotherapy targets motor and gait recovery; occupational therapy supports return to activities of daily living; speech and language therapy addresses aphasia, dysarthria and dysphagia; clinical neuropsychology supports cognitive and mood recovery; clinical nursing and dietetic input round out the multidisciplinary picture. The integrated community stroke service model extends this into home-based rehabilitation in well-resourced areas.

The effect size of structured high-intensity rehabilitation in stroke recovery is, by an order of magnitude, the largest of any post-acute intervention. No peptide has been shown to come close.

PSCI and Vascular Cognitive Impairment Pharmacotherapy

Cholinesterase inhibitors (donepezil, rivastigmine, galantamine) and the NMDA antagonist memantine are licensed for Alzheimer's disease in the UK. Their use in pure vascular cognitive impairment or vascular dementia is off-label in most NHS pathways, the evidence base is modest, and effect sizes on cognitive composite scores are small to moderate. Reviews of PSCI management conclude that no pharmacological agent has high-quality evidence for benefit in this population.

This is the gap into which interest in unlicensed neuroplasticity-targeted compounds (Dihexa, Semax, Selank, cerebrolysin, citicoline) flows. The honest answer is that none of these have trial-grade evidence in PSCI either; some are more widely used in clinical practice in parts of Eastern Europe and Russia with weaker regulatory standards, which is a fact about regulatory environments rather than about evidence.

Risk Profile Comparison

NHS-licensed stroke-prevention and rehabilitation drugs have well-characterised risk profiles built up over decades of trials and post-marketing surveillance. Dihexa's risk profile is, by contrast, poorly characterised in any human population, and uncharacterised entirely in stroke survivors. The theoretical concerns flagged on the side effects page — c-Met activation in tissues where the proto-oncogene is implicated in cancer (breast, lung, gastric, colorectal), interactions with the renin-angiotensin system relevant to blood pressure control after stroke, uncharacterised effects on platelet function relevant to bleeding risk, vivid dream intensification possibly affecting sleep architecture — matter more in a stroke population than in healthy controls.

2026 Stroke News: What Is Actually Happening This Year

For SEO transparency and reader value, the following 2025-2026 events frame the contemporary UK stroke recovery landscape and are referenced where relevant in this article:

• 2025 — ESO aphasia rehabilitation guideline published: Brady et al. in International Journal of Stroke set a minimum 20-hour total therapy dose and embraced digital and group delivery models. The most authoritative European guidance on aphasia rehabilitation to date.
• 2025-2026 — UK mechanical thrombectomy expansion continues: Under the NHS Long Term Plan and NHS England's stroke programme. Approximately 15% of admitted stroke patients are eligible by current trial criteria, but only ~25% of eligible patients currently receive the procedure — the workforce and capacity gap is the rate-limiting step. McMeekin and colleagues (2024) European Stroke Journal document the modelling.
• 2026 — Frontiers network meta-analysis of non-pharmacological PSCI interventions: Comparative efficacy analysis suggesting combined computer-based cognitive training plus tDCS is the optimal non-pharmacological option for patients with prominent cognitive deficits.
• 2026 — Updated AHA/ASA scientific statement on cognitive impairment after stroke: Mac Grory and colleagues consolidated current understanding of PSCI incidence (~60% in the first year), heterogeneity, screening recommendations and treatment landscape.
• 2026 — Frontiers systematic review of novel PSCI therapies: Systematic review covering pharmacological repurposing candidates, non-invasive brain stimulation, exercise, cognitive training and emerging biomarkers — concluding that existing treatments show limited efficacy.
• 2026 — Imaging research advances in PSCI: Frontiers in Neuroimaging review on diagnostic and treatment advances using advanced MRI and connectomic approaches.
• 2026 — Tenecteplase use expanding in UK hyperacute stroke: Several UK regions have moved or are moving from alteplase to tenecteplase as the default thrombolytic, on the basis of non-inferiority data and operational advantages (bolus rather than infusion). Service-level implementation is variable.
• SSNAP data locking continues quarterly: The Sentinel Stroke National Audit Programme continues to capture >95% of UK hospital stroke admissions, with the next data-locking deadline for January-March 2026 on 5 May 2026.
• October 2023 — NICE NG236 still the active rehabilitation guideline: NICE stroke rehabilitation guidance remains in force and recommends ≥3 hours/day, 5 days/week of multidisciplinary therapy.
• 2024 — Fosgonimeton LIFT-AD failed: The closest clinical-stage relative of Dihexa missed its primary endpoint in mild-to-moderate Alzheimer's disease, and Athira Pharma's broader HGF/MET-positive-modulator programme was wound down. The fosgonimeton stroke programme that was sometimes anticipated never materialised. See the fosgonimeton review.

The 2026 trajectory for stroke care in the UK is, on balance, cautiously optimistic on the acute side (continued thrombectomy expansion, tenecteplase rollout, audit-driven service improvement) and stubbornly difficult on the post-acute cognitive side (no licensed PSCI drug, variable community rehabilitation access, persistent unmet need in long-term aphasia). It is precisely this asymmetric picture that drives interest in unlicensed neuroplasticity-targeted peptides — understandable patient interest in an environment where licensed options are limited.

Post-Stroke Depression: A Major Confound and a Mechanistic Bridge

Post-stroke depression affects approximately 30% of stroke survivors and has effects on rehabilitation engagement, cognitive recovery, recurrent stroke risk and mortality. It is also a clinical territory where the synaptogenic-neuroplasticity hypothesis of depression — explored in detail in the depression and mood review — intersects directly with stroke recovery biology.

The Biology of Post-Stroke Depression

Post-stroke depression is not simply a psychological reaction to disability. Lesion-network mapping studies have identified specific stroke territories (left frontal, basal ganglia, possibly limbic) where infarction confers higher post-stroke depression risk independent of disability severity. Reduced BDNF signalling, hippocampal volume loss, microstructural changes in the dorsolateral prefrontal cortex and disruption of cortico-limbic connectivity all contribute. The synaptogenic hypothesis of depression — which has driven much of the recent interest in ketamine, psilocybin and other rapid-acting antidepressants — applies as directly to post-stroke depression as to primary depression.

PSD Treatment

NHS-recommended treatment for post-stroke depression is SSRIs (sertraline, citalopram) with consideration of mirtazapine for sleep-disrupted phenotypes, structured psychological therapy where accessible, and aerobic exercise. The FOCUS, AFFINITY and EFFECTS trials (sertraline / fluoxetine for stroke recovery, irrespective of depression status) collectively cooled enthusiasm for routine post-stroke SSRI use as a recovery-promoting agent — the rationale is now restricted to treatment of established depression.

For Dihexa in this territory, no human data exist. The synaptogenic-hypothesis-of-depression case is consistent across PSD and primary depression, the HGF/c-Met biology overlaps directly with the substrate of post-stroke recovery, and the mechanistic argument is therefore reasonable. The clinical reality remains: established post-stroke depression should be treated with evidence-based care under GP, psychiatry or stroke-team supervision; an unstudied peptide is not part of the appropriate response.

Practical Realities: If Someone Is Determined to Self-Experiment Anyway

This site exists because people will research Dihexa whether or not we cover it. The honest editorial position for stroke survivors specifically is that the hyperacute and early-subacute phases (the first three months) are an absolute “not yet”: this is the period of secondary-prevention optimisation, intensive multidisciplinary rehabilitation under NICE NG236, and active medication titration where any unstudied peptide is a clear risk-benefit failure. Beyond that, in the chronic phase, the honest harm-reduction frame for someone determined to self-experiment looks like the following.

Specific to Stroke: When Not to Self-Experiment

A reasonable list of absolute and relative contraindications for the stroke survivor population, drawing on the broader side effects review:

• Anyone within the first three months of an acute stroke. The hyperacute and early-subacute pathway is too active and the haemorrhagic-conversion risk too elevated to add anything unstudied.
• Anyone with a haemorrhagic stroke or intracerebral haemorrhage of any cause within the previous 12 months.
• Anyone on warfarin, DOAC or dual antiplatelet therapy without prescriber awareness and oversight.
• Anyone with poorly controlled hypertension or with active blood pressure titration in progress.
• Anyone with established post-stroke depression, anxiety or PTSD where capacity-relevant cognitive symptoms are present.
• Anyone with established post-stroke seizures, particularly if anticonvulsant titration is incomplete.
• Anyone with a personal or strong family history of breast, ovarian, lung, gastric or colorectal cancer (c-Met-implicated tissues).
• Anyone whose cognitive picture has not been formally evaluated — the diagnostic clarity of a clean baseline matters more than experimental neuroplasticity.
• Anyone who has not yet maximised their structured rehabilitation programme. Adding a peptide to suboptimal SLT/OT/PT exposure makes no mechanistic sense and is the wrong order of operations.

Dosing Considerations Specific to Stroke Survivors

The community dose range for Dihexa, drawn from the 2026 review of self-reported protocols, is typically 8-25 mg/day orally or sublingually for 8-16 weeks, often cycled. Several considerations argue for the lower end of this range in stroke survivors specifically:

• Polypharmacy is the rule. Five-to-ten regular medications is common after stroke (antiplatelet or anticoagulant, statin, two or more antihypertensives, possibly an SSRI, gabapentinoid or anticonvulsant). Interactions across this combination with an unstudied peptide are unknowable.
• Cardiovascular and blood-pressure regulation is post-stroke unstable in many patients, and an angiotensin IV-derived peptide may have uncharacterised effects on this system.
• Sleep architecture is often disturbed after stroke — consider the vivid-dream effect carefully if the patient already has fragmented or non-restorative sleep.
• Cognitive baseline matters. A patient with significant PSCI may lack reliable capacity to monitor or report their own response to an experimental intervention.

Monitoring

If self-experimentation proceeds despite the foregoing — and in the early period after stroke it should not without specialist neurology input — minimum monitoring should include: subjective cognitive and functional symptom diary; standing and sitting blood pressure; baseline blood panel before and after each cycle (FBC, U&Es, LFTs, lipids, B12, folate, ferritin, TFTs, HbA1c, INR if on warfarin); sleep journal; and prompt reporting to the responsible GP and stroke team of any change in baseline trajectory. New or worsening cognitive symptoms, sudden onset of confusion, severe headaches, vision changes, focal neurological symptoms or any feature suggestive of recurrent stroke are stop-and-call-999 events.

When to Stop Immediately

Sudden onset of new focal weakness, speech disturbance, facial droop, severe headache, vision changes or any FAST-positive symptom requires emergency evaluation regardless of cause — call 999. Any new chest pain, palpitations, syncope, fall or unexplained bruising or bleeding warrants urgent medical attention. Any confirmed cancer diagnosis or strong family history of c-Met-implicated cancers should trigger immediate cessation pending oncology input. Any unexplained change in cognitive trajectory should prompt review with the responsible clinician.

The Evidence-Based 2026 Stroke Recovery Plan: What to Actually Do

If you take one section of this article seriously, take this one. For someone who has had a stroke or TIA in the UK in 2026, here is the order of operations with the strongest evidence base.

1. Maximise secondary prevention. Antiplatelet or anticoagulant as appropriate, high-intensity statin, blood pressure to target (typically <130/80), HbA1c optimisation, smoking cessation, alcohol within UK guidelines. The cumulative effect on recurrent stroke risk is the highest-yield single intervention available. NHS stroke recovery guidance sets out the standard package.
2. Engage in structured multidisciplinary rehabilitation. NICE NG236 recommends ≥3 hours/day, 5 days/week. Physiotherapy, occupational therapy, speech and language therapy, neuropsychology and clinical nursing input as needed. Early supported discharge and integrated community stroke service models extend rehabilitation into the home where available. Adherence to the prescribed therapy dose is the single most important determinant of functional recovery.
3. Hit the 20-hour aphasia therapy minimum if you have aphasia. The 2025 ESO aphasia guideline sets this floor — ask your speech and language therapist explicitly about total dose and consider digital and group-therapy intensification (see Stroke Association communication tools).
4. Address post-stroke depression aggressively. Around 30% of survivors develop PSD, which independently impairs rehabilitation engagement and cognitive recovery. SSRIs, structured psychological therapy, aerobic exercise and stroke-specific support groups all have evidence.
5. Build a structured exercise programme. Aerobic exercise raises BDNF, supports cardiovascular secondary prevention, improves mood and cognition, and is one of the highest-yield single interventions available across the recovery timeline. Stroke-specific exercise programmes (the Stroke Association's local groups, NHS-funded community rehabilitation, dance-based programmes, tai chi) all have published evidence.
6. Manage cognitive load and sleep. Address sleep apnoea (very common after stroke), optimise sleep hygiene, treat post-stroke fatigue and pacing concerns. Sleep disorders are an under-recognised driver of PSCI trajectory.
7. Consider clinical trial participation. UK stroke research is concentrated in specialist centres affiliated with the NIHR Stroke Research Network, and trials cover everything from acute reperfusion to long-term cognitive rehabilitation. Ask your stroke team about local trial availability; the Stroke Association's research hub catalogues recruiting studies.
8. Address general brain health. The 2024 Lancet Commission's 14 modifiable dementia risk factors (hearing aids, vision optimisation, blood pressure control, alcohol within guidelines, smoking cessation, exercise, social engagement, air pollution exposure) overlap heavily with vascular cognitive risk — see the MCI & brain aging review.
9. Plan ahead. Lasting power of attorney, advance care planning, conversations with family. Stroke is associated with elevated risk of recurrence and of progressive cognitive decline; planning early is a kindness to future-you.

The Bottom Line: A Strong Mechanism, A Real Patient Need, Zero Human Dihexa Data

The 2026 reading on Dihexa for stroke recovery is, in our editorial view, mechanistically the most coherent on this site outside the directly degenerative indications. The HGF/c-Met system is a documented endogenous post-stroke repair signal that rises within hours of ischaemic stroke and remains elevated for weeks. BDNF is the substrate of every rehabilitation programme and the target of the highest-evidence non-pharmacological interventions (aerobic exercise, cognitive-motor rehabilitation, intensive SLT). Vascular cognitive impairment and post-stroke cognitive impairment share a synaptic-loss biology with the MCI and Alzheimer's cognitive phenotypes where the synaptogenic-peptide rationale is most developed. The aphasia recovery story is one of the clearest examples of experience-dependent neuroplasticity in clinical neurology, and a peptide that potentiates the same plasticity substrate is, on paper, mechanistically attractive.

And yet: there is no controlled human trial of Dihexa in ischaemic stroke, haemorrhagic stroke, PSCI, vascular cognitive impairment, post-stroke aphasia or post-stroke depression. The closest clinical-stage relative, fosgonimeton, was never advanced into stroke trials and was wound down after the 2024 LIFT-AD Alzheimer's failure. The safety profile in stroke survivors is wholly uncharacterised in a population on polypharmacy with cardiovascular comorbidity and active secondary-prevention optimisation. The hyperacute and early-subacute phases are an absolute “not yet.” The chronic phase has more room to consider experimental adjuncts, but only after the evidence-based pathway has been fully exhausted — and most patients have not.

The honest 2026 reading: NHS-pathway secondary prevention and NICE-compliant high-intensity multidisciplinary rehabilitation first, with explicit attention to the 20-hour ESO aphasia minimum if relevant; post-stroke depression treatment and structured exercise next; clinical-trial referral if interested in experimental approaches; and unlicensed peptides essentially last — if at all. The mechanistic case for an HGF/c-Met modulator in stroke recovery deserves a real trial. Self-experimentation is not what that trial looks like, and it is not the right next step for most readers of this page.

Frequently Asked Questions

Related Reading on Dihexa.co.uk

• Dihexa for ALS & Motor Neurone Disease (MND) — the motor-system companion piece on HGF/c-Met motor neuron protection, Engensis (VM202), the May 2026 Longitude Prize on ALS Discovery Awards and the EXPERTS-ALS / MND-SMART trial pipeline.
• Dihexa for TBI, Concussion & Stroke Recovery — the neurorepair indication that shares the synaptic-rebuilding rationale with stroke at the cellular level.
• Dihexa for MCI & Brain Aging — the synaptic-loss case directly relevant to vascular cognitive impairment.
• Dihexa for Parkinson's Disease — the closest fellow neurodegeneration review with the SHAPE PDD/DLB cognitive signal.
• Dihexa for Multiple Sclerosis (MS) — demyelination, remyelination and the HGF/c-Met biology shared with stroke white-matter recovery.
• Dihexa & Alzheimer's Research — the academic origin story shared with the small-vessel-disease-Alzheimer mixed-pathology picture.
• Dihexa vs BDNF — the central potency claim, examined; BDNF is the rehabilitation substrate.
• Dihexa for Depression & Mood — the synaptogenic hypothesis of depression, directly relevant to post-stroke depression.
• Dihexa for Anxiety & Chronic Stress — the post-stroke anxiety phenotype.
• Dihexa for Long COVID Brain Fog — another major neuroinflammation indication with overlapping biology.
• Dihexa, Sleep & Memory Consolidation — the vivid-dream effect and post-stroke sleep architecture.
• Dihexa for Chemo Brain (CICI) — another cognitive recovery indication with overlapping neuroinflammation biology.
• Dihexa for Menopause Brain Fog — the BDNF axis and a closely related cognitive symptom phenotype.
• Dihexa for ADHD — the prefrontal cortex angle on the same broader synaptic story.
• Fosgonimeton & Athira — the closest clinical-stage relative and why it was never advanced into stroke trials.
• Dihexa Review 2026 — effects timeline, oral vs sublingual, cycling protocols.
• Dihexa Stacking Guide — why combining Dihexa with stroke prevention drugs needs prescriber oversight.
• Dihexa for Cognitive Enhancement — the broader cognition conversation.
• Mechanism of Action — HGF/c-Met, PI-3K/AKT, dendritic spines.
• Benefits Overview — the broader claimed-benefit landscape, evidence-rated.
• Dosage Guide — community dose ranges and considerations.
• Side Effects & Risks — the general safety picture, including stroke-relevant antiplatelet/anticoagulant concerns.
• UK Legal Status — where Dihexa sits in UK law and MHRA advertising rules.
• Research & Studies — the human and animal evidence base reviewed.
• Dihexa vs Other Nootropics — how Dihexa compares with Semax, Selank, Noopept, BPC-157, cerebrolysin and citicoline for cognitive indications.
• Glossary — technical terms used on this page.
• Full Site FAQ — the broader question set across the site.

External Authoritative Sources Cited

• Stroke Association. UK stroke statistics — 100,000 strokes per year and 1.3 million survivors.
• Stroke Association (UK national charity, helpline 0303 3033 100).
• Stroke Association. Mechanical thrombectomy for ischaemic stroke.
• Stroke Association. Communication treatment and tools for aphasia.
• NICE NG236 — Stroke rehabilitation in adults (October 2023).
• NHS UK. Stroke: Recovery.
• NHS England. Work on stroke.
• Sentinel Stroke National Audit Programme (SSNAP).
• House of Commons Library. World Stroke Day briefing.
• Brady MC et al. European Stroke Organisation (ESO) guideline on aphasia rehabilitation (2025).
• McMeekin P et al. Modelled annual thrombectomy eligibility of UK stroke patients (European Stroke Journal, 2024).
• Mac Grory B et al. Cognitive Impairment Following Ischemic and Hemorrhagic Stroke: AHA/ASA Scientific Statement.
• Novel therapies for post-stroke cognitive impairment: a systematic review (Frontiers in Neurology, 2025/2026).
• Comparative efficacy of non-pharmacological interventions for post-stroke cognitive impairment (Frontiers, 2026 network meta-analysis).
• Imaging research, diagnosis and treatment advances of post-stroke cognitive impairment (Frontiers in Neuroimaging, 2026).
• Effects of Cognitive-Motor Interventions on Serum BDNF Levels in Adults and Older Population Post-Stroke (Frontiers in Pharmacology, 2026 meta-analysis).
• Effect of Exercise on Brain-Derived Neurotrophic Factor in Stroke Survivors: A Systematic Review and Meta-Analysis (Stroke, 2023).
• Schabitz WR et al. Intravenous brain-derived neurotrophic factor enhances post-stroke sensorimotor recovery and stimulates neurogenesis (Stroke).
• Brain repair mechanisms after cell therapy for stroke (Brain, 2024).
• HGF and MET: From Brain Development to Neurological Disorders (Frontiers in Cell and Developmental Biology, 2021).
• Wright JW & Harding JW. The development of small molecule angiotensin IV analogs to treat Alzheimer's and Parkinson's diseases (Neuroscience, 2015).
• Benoist CC et al. The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the HGF/c-Met system.
• Pendlebury ST & Rothwell PM. Update on the prevalence of dementia after TIA and stroke (PubMed).
• Big CACTUS: computerised speech and language therapy for long-term post-stroke aphasia (NIHR HTA monograph).
• University of Manchester. New method could transform aphasia treatment after stroke.
• NIHR Be Part of Research portal.
• Different Strokes — UK charity supporting younger stroke survivors.
• Headway — the UK acquired brain injury association.
• Aphasia Re-Connect — UK aphasia support.